Nov 2026· Frontiers in Cell and Developmental Biology· 0 citations· 137 references
TL;DR
Overall, this review not only elucidates the mechanisms by which mitochondrial metabolic reprogramming drives tumor immune evasion but also provides a theoretical basis for optimizing metabolism-targeted immunotherapy.
Abstract
The complexity of the tumor microenvironment often leads to resistance to cancer immunotherapy, and mitochondrial metabolic reprogramming is an important mechanism underlying tumor immune evasion. Treatment selection and response prediction remain challenging because the mechanisms of resistance and changes in the tumor immune microenvironment are incompletely understood. Therefore, a comprehensive understanding of immunotherapy resistance will facilitate the development of targeted strategies to overcome resistance. This review synthesizes the manifestations and consequences of mitochondrial metabolic reprogramming in tumor cells and summarizes how tumor-derived metabolites shape an immunosuppressive TME. It focuses on how mitochondrial metabolic reprogramming in antitumor immune cells, including CD8
+
T cells, dendritic cells, M1-like tumor-associated macrophages, and natural killer cells, and in immunosuppressive cells, including regulatory T cells, myeloid-derived suppressor cells, and M2-like tumor-associated macrophages, contributes to the exhaustion of antitumor immunity and promotes tumor immune evasion. This review examines how mitochondrial metabolism can be targeted to overcome immunotherapy resistance and summarizes the mechanisms and current status of related immunotherapeutic strategies. It also discusses the current bottlenecks and future directions of metabolism-targeted cancer immunotherapy. Overall, this review not only elucidates the mechanisms by which mitochondrial metabolic reprogramming drives tumor immune evasion but also provides a theoretical basis for optimizing metabolism-targeted immunotherapy.
Pancreatic cancer is one of the most lethal malignancies of the digestive system, and its profoundly immunosuppressive tumor microenvironment (TME) represents a major driver of tumor progression and therapeutic resistance. Emerging evidence indicates that metabolic reprogramming profoundly influences the polarization,...
Gang-Zhao Gu, Yang Du, Heng-Zhi Zhang et al.· Frontiers in Immunology· 0 citations
This review delineates how mitochondrial transfer exerts dual effects on antitumor immunity: tumor cells hijack functional mitochondria from T cells, macrophages, and stromal cells to fuel their proliferation and therapy resistance, while simultaneously delivering mutant mitochondria to immune cells to drive exhaustion...
This study explores the reversal effect of targeting mitochondrial metabolic reprogramming on CD8⁺ T cell exhaustion within the tumor microenvironment and its synergistic mechanism when combined with immune checkpoint blockade therapy. B16-OVA melanoma and LLC lung cancer tumor-bearing mouse models were established. Us...
Gang Liu, Jia Wang, Alena Mikalaeuna Vasiukevich et al.· Biology and Medical Engineer...· 1 citation
Colorectal cancer (CRC) is one of the most prevalent malignancies of the gastrointestinal tract worldwide. Notably, most patients with microsatellite-stable (MSS) tumors show primary resistance to immune checkpoint inhibitors (ICIs), creating an unmet clinical need. The mechanisms underlying immune evasion and strategi...
Dai-Xun Ding, Jing-Yi Hu, Yi-Tong Wang et al.· International Journal of Mol...· 0 citations
Metabolic reprogramming is a core feature of tumor cells in adapting to microenvironmental stress and acquiring malignant phenotypes. It not only supports rapid proliferation but also mediates immune escape by reshaping the immune microenvironment. In recent years, the “metabolism-immune axis”, serving as a central hub...
Jin-Ru Yang, Xing Cai, Fa-Jian He et al.· Signal Transduction and Targ...· 0 citations
Smart nanodelivery systems can improve the in vivo stability, tumor accumulation, TAM exposure, and spatiotemporal release of immunomodulators, small-molecule inhibitors, nucleic acid therapeutics, cytokines, and macrophage immune-checkpoint modulators, thereby improving efficacy while reducing systemic toxicity.